

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**GENERTEC UNIVERSAL MEDICAL GROUP COMPANY
LIMITED**

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 2666)

**ANNOUNCEMENT IN RELATION TO THE PROPOSED ISSUANCE OF 2025
RENEWABLE CORPORATE BONDS (TRANCHE 1) IN THE PRC
BY CHINA UNIVERSAL LEASING CO., LTD.,
A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY**

This announcement is made by Genertec Universal Medical Group Company Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

China Universal Leasing Co., Ltd. (中國環球租賃有限公司) (the “**Issuer**”), a wholly-owned subsidiary of the Company, has received the approval from China Securities Regulatory Commission (“**CSRC**”) on the issuance of the renewable corporate bonds of an aggregate principal amount up to RMB2.00 billion to qualified investors in the People’s Republic of China (the “**PRC**”). As of the date of this announcement, the balance of the principal amount was RMB1.50 billion. Such bonds would be issued in installments. The total principal amount of this tranche of the bonds (the “**Bonds**”) is no more than RMB1.00 billion (inclusive). The Bonds is divided into two types: (i) type 1 with a basic term of 2 years; and (ii) type 2 with a basic term of 3 years. The Bonds will bear a repricing period equal to the length of its basic term, and the Issuer will, at the end of the agreed basic term and each repricing period, be entitled to an option to extend the term of the Bonds for one

repricing period, or fully repay the Bonds. The Bonds will be attached with inter-type callback option, the extension option, deferred interest payment right and redemption option of the Issuer. During the first term, the Bonds will have a fixed interest rate which will be determined at the end of the subscription period through book building process. The coupon rate will be the aggregation of the initial benchmark interest rate and the initial interest rate spread, and it will be reset once in each term. The coupon rate for the subsequent term will be adjusted to the aggregation of the benchmark interest rate for such term, the initial interest rate spread, and 300 basis points. The net proceeds from the issuance of the Bonds will be used by the Issuer as its supplementary operating funds.

The Bonds will be issued off-line to qualified investors as defined under the Administrative Measures for the Issuance and Trading of Corporate Bonds (《公司債券發行與交易管理辦法》) by price enquiring and placing. Tianfeng Securities Co., Ltd. (天風證券股份有限公司), China Great Wall Securities Co., Ltd. (長城證券股份有限公司), Everbright Securities Company Limited (光大證券股份有限公司), Shenwan Hongyuan Securities Co., Ltd. (申萬宏源證券有限公司) and China International Capital Corporation Limited (中國國際金融股份有限公司) are the joint lead underwriters for the issuance of the Bonds.

Other principal terms of the Bonds to be issued are as follows:

Place of issuance: The Shanghai Stock Exchange

Par value: RMB100.00

Issue price: RMB100.00

Credit rating: AAA rating for the Issuer, as assessed by China Lianhe Credit Rating Co. Ltd. (聯合資信評估股份有限公司) on 27 February 2025.

Trading arrangement: The Bonds are expected to be issued off-line from 6 March 2025.

In accordance with the relevant laws and regulations in the PRC, relevant documents in relation to the Issuer and the Bonds will be published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>). Shareholders of the Company and potential investors are reminded that such documents were prepared in accordance with the requirements in the PRC and are limited solely to the Issuer, and the information contained therein does not provide a full picture of the operation status of the Company and its subsidiaries.

According to the approval from the CSRC, the issuance of the remaining bonds would be completed within 24 months from the date of such approval. Further announcement(s) will be made by the Company in relation to the updated progress of issuance of the Bonds and the issuance of the remaining bonds as and when appropriate.

By order of the Board
**Genertec Universal Medical Group Company
Limited**
通用環球醫療集團有限公司
Chen Shisu
Chairman of the Board

Beijing, PRC, 5 March 2025

As at the date of this announcement, the executive directors of the Company are Mr. Chen Shisu (Chairman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive directors of the Company are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.